REFERENCES

1. Warrell DA. Venomous bites, stings, and poisoning. Infectious Disease Clinic of North America. June 2012; Vol 26(2):207-223.
2. Garb JE, Hayashi CY. Molecular evolution of α-latrotoxin, the exceptionally potent vertebrate neurotoxin in black widow spider venom. Molecular Biology Evolution. May 2013; Issue 30(5):999-1014.
3. Maretić Z. Latrodectism: variations in clinical manifestations provoked by Latrodectus species of spiders. Toxicon. 1983; Vol 21, Issue (4):457-66.
4. Halmo LS, Hurst IA, Ng PC, Wang GS. Latrodectus Facies after Latrodectus Hesperus Envenomation in a Pediatric Patient. Journal of Emergency Medicine. Oct 2019; Vol 57, Issue (4):523-526.
5. Ramialiharisoa A, de Haro L, Jouglard J, Goyffon M. Le latrodectisme à Madagascar [Latrodectism in Madagascar]. Medecine Tropicale (Mars). Dec 1993; Vol 54, Issue (2):127-30.
6. Dart RC, Bush SP, Heard K, et al. The efficacy of antivenin latrodectus (black widow) equine immune F(ab')2 versus placebo in the treatment of latrodectism: a randomized, double-blind, placebo-controlled, clinical trial. Annals of Emergency Medicine. Sep 2019; Vol 74, Issue (3):439-449.
7. Offerman SR, Daubert GP, Clark RF. The treatment of black widow spider envenomation with antivenin latrodectus mactans: a case series. The Permanente Journal. Summer 2011; Vol 15, Issue (3):76-81. doi: 10.7812/tpp/10-136.
8. Nordt SP, Clark RF, Lee A, Berk K, Lee Cantrell F. Examination of adverse events following black widow antivenom use in California. Clinical Toxicology (Phila). Jan 2012; Vol 50(1):70-73.
9. Sánchez EE, Migl C, Suntravat M, Rodriguez-Acosta A, Galan JA, Salazar E. The neutralization efficacy of expired polyvalent antivenoms: An alternative option. Toxicon. Oct 2019; Vol 168:32-39.
10. Isbister GK, O'Leary M, Miller M, Brown SG, Ramasamy S, James R, Schneider JS. A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. British Journal of Clinical Pharmacology. Jan 2008; Vol 65(1):139-43.
11. Goddard J. Physician's guide to arthropods of medical importance. CRC press; 19 Apr 2016.
12. Chaim OM, Trevisan-Silva D, Chaves-Moreira D, et al. Brown spider (loxosceles genus) venom toxins: Tools for biological purposes. Toxins (Basel). Mar 2011; Vol 3(3):309-344.
13. Kurpiewski G, Forrester LJ, Barrett JT, Campbell BJ. Platelet aggregation and sphingomyelinase D activity of a purified toxin from the venom of Loxosceles reclusa. Biochimica et Biophysica Acta (BBA). 18 Dec 1981; Vol 678(3):467-476.
14. Robinson JR, Kennedy VE, Doss Y, Bastarache L, Denny J, Warner JL. Defining the complex phenotype of severe systemic loxoscelism using a large electronic health record cohort. PLoS One. 19 Apr 2017 ; Vol 12(4):e0174941.
15. Swanson DL, Vetter RS. Bites of brown recluse spiders and suspected necrotic arachnidism. New England Journal of Medicine. 17 Feb 2005; Vol 352 (7):700-707.
16. Said A, Hmiel P, Goldsmith M, Dietzen D, Hartman ME. Successful use of plasma exchange for profound hemolysis in a child with loxoscelism. Pediatrics. Nov 2014; Vol 134(5):e1464-7.
17. Kong EL, Hart KK. Tarantula Spider Toxicity. 31 May 2020. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
18. Nimorakiotakis B, Winkel KD. The funnel web and common spider bites. Australian Family Physicians. April 2004; Vol 33(4):244-251.
19. Hodgson WC. Pharmacological action of Australian animal venoms. Clinical and Experimental Pharmacology and Physiology. Jan 1997; Vol 24(1):10-17.
20. Isbister GK, Sellors KV, Beckmann U, Chiew AL, Downes MA, Berling I. Catecholamine-induced cardiomyopathy resulting from life-threatening funnel-web spider envenoming. The Medical Journal of Australia. 5 Oct 2015; Vol 203(7):302-304.
21. Braitberg G, Segal L. Spider bites - Assessment and management. Australian Family Physicians. Nov 2009; Vol 38(11):862-7.
22. Chippaux JP, Goyffon M. Epidemiology of scorpionism: a global appraisal. Acta Tropica. Aug 2008; Vol 107, Issue 2:71-79.
23. Goyffon M, Vachon M, Broglio N. Epidemiological and clinical characteristics of the scorpion envenomation in Tunisia, Toxicon. 1982; Vol 20:337-344.
24. O'Connor A, Ruha AM. Clinical course of bark scorpion envenomation managed without antivenom. Journal of Medical Toxicology. Sep 2012; Vol 8(3):258-262.
25. Bahloul M, Chaari A, Dammak H, et al. Pulmonary edema following scorpion envenomation: mechanisms, clinical manifestations, diagnosis and treatment. International Journal of Cardiology. 10 Jan 2013; Vol 162(2):86-91.
26. Dehghani R, Charkhloo E, Seyyedi-Bidgoli N, et al. A Review on Scorpionism in Iran. Journal of Arthropod-Borne Disease. 25 Dec 2018; Vol 12(4):325-333. eCollection 2018 Dec.
27. Cupo P. Clinical update on scorpion envenoming. Revista da Sociedade Brasileira Medicina Tropical. Nov-Dec 2015; Vol 48(6):642-649.
28. Dizaji R, Sharafi A, Pourahmad J, et al. The effects of Hemiscorpius lepturus induced-acute kidney injury on PGC-1α gene expression: From induction to suppression in mice. Toxicon. 30 Jan 2020; Vol 174:57-63.
29. Chakroun-Walha O, Karray R, Jerbi M, et al. Value of troponin levels in the diagnosis of cardiac dysfunction in moderate scorpion envenomation. Human and Experimental Toxicology. Jun 2018; Vol 37(6):580-586.
30. Sagheb MM, Sharifian M, Moini M, Sharifian AH. Scorpion bite prevalence and complications: report from a referral centre in southern Iran. Tropical Doctor. Apr 2012; Vol 42(2):90-91.
31. Rodrigo C, Gnanathasan A. Management of scorpion envenoming: a systematic review and meta-analysis of controlled clinical trials. Systematic Reviews. 8 Apr 2017; 6(1): Article 74.
32. Prasad R, Mishra OP, Pandey N, Singh TB. Scorpion sting envenomation in children: factors affecting the outcome. Indian Journal of Pediatrics. May 2011; Vol 78(5):544-548.
33. Abroug F, ElAtrous S, Nouira S, et al. Serotherapy in scorpion envenomation: a randomised controlled trial. Clinical Trial Lancet. 11 Sep 1999; Vol 354, Issue (9182):906-909. doi: 10.1016/s0140-6736(98)12083-4.
34. Boyer L, Degan J, Ruha A-M, et al. Safety of intravenous equine F(ab’)2: Insights following clinical trials involving 1534 recipients of scorpion antivenom. Toxicon. Dec 2013; Vol 76:386-393.
35. León G, Herrera M, Segura Á, Villalta M, Vargas M, Gutiérrez JM. Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms. Toxicon. 15 Dec 2013; Vol 76:63-76.
36. Dhami S, Panesar SS, Roberts G, et al. Management of anaphylaxis: a systematic review. Allergy. Feb 2014; Vol 69(2):168-175. doi:10.1111/all.12318.
37. Simons FER, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal J. 2015; Vol 8(1):32. doi:10.1186/s40413-015-0080-1.
38. Simons FER, Ardusso LRF, Bilò MB, et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Current Opinion Allergy Clinical Immunology. Aug 2012; Vol 12(4):389-399. doi:10.1097/ACI.0b013e328355b7e4.
39. Isbister GK, Bawaskar HS. Scorpion envenomation. New England Journal of Medicine. 31 July 2014; Vol 371(5):457-63.